Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 2; peer review: 2 approved]
| Autor: | Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | F1000Research, Vol 11 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2046-1402 64457931 |
| DOI: | 10.12688/f1000research.128074.2 |
| Popis: | Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and child. However, there is a lack of information on the transfer of these drugs into the developing brain. Methods: Sprague Dawley rats at three developmental ages: embryonic day E19, postnatal day P4 and non-pregnant adult females were administered unlabelled or radiolabelled (3H) olanzapine (0.15 mg/kg) either as monotherapy or in combination with each of seven other common medications. Similar injections were administered to pregnant E19 females to investigate placental transfer. Olanzapine in plasma, cerebrospinal fluid (CSF) and brain was measured by liquid scintillation counting after a single dose (acute) or following 5 days of treatment (prolonged). Results: Olanzapine entry into brain and CSF was not age-dependent. Prolonged olanzapine treatment reduced placental transfer from 53% to 46% (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|